据港交所12月29日披露，悦康药业集团股份有限公司(简称：悦康药业(688658.SH))向港交所主板提交上市申请，中信证券为其独家保荐 人。招股书披露，悦康药业是一家生物制药公司，专注于研究、开发、生产和商业化四种模式的疗法：寡核苷酸、信使核糖核酸(mRNA) 疫苗、多肽和中药创新药。公司利用商业化产品组合、跨模态研发技术平台和能力、药品生产质量管理规范(GMP) 认证的生产系统及遍 布全国的商业化网络等综合优势，为拥有大量未满足需求及长期增长潜力的主要治疗领域推进候选产品的差异化创新管线。 | 篇纂]的[編纂]數目 : [編纂]股H股(視乎[編纂] | | | | --- | --- | --- | | 行使與否而定) | | | | [編纂]數目 | .. | 「編纂】股H股(可予重新分配) | | [編纂]數目 | | : [編纂]股H股(可予重新分配及 | | 視乎[編纂]行使與否而定） | | | | 最高[編纂] : | | 每股H股[編纂]港元,另加1.0%經紀 | | 佣金、0.00015% 會財局交易徵費、 | | | | 0.0027％證監會交易徵費及0.00565% | | | | 聯 ...

智通财经APP获悉，据港交所12月29日披露，悦康药业集团股份有限公司(简称：悦康药业(688658.SH))向港交所主板提交上市申请，中信 证券为其独家保荐人。招股书披露，悦康药业是一家生物制药公司，专注于研究、开发、生产和商业化四种模式的疗法：寡核苷酸、信使 核糖核酸(mRNA)疫苗、多肽和中药创新药。公司利用商业化产品组合、跨模态研发技术平台和能力、药品生产质量管理规范(GMP) 认证 的生产系统及遍布全国的商业化网络等综合优势，为拥有大量未满足需求及长期增长潜力的主要治疗领域推进候选产品的差异化创新管 线。 ...

智通财经APP获悉，据港交所12月29日披露，悦康药业集团股份有限公司(简称：悦康药业(688658.SH))向港交所主板提交上市申请，中信 证券为其独家保荐人。招股书披露，悦康药业是一家生物制药公司，专注于研究、开发、生产和商业化四种模式的疗法：寡核苷酸、信使 核糖核酸(mRNA)疫苗、多肽和中药创新药。公司利用商业化产品组合、跨模态研发技术平台和能力、药品生产质量管理规范(GMP) 认证 的生产系统及遍布全国的商业化网络等综合优势，为拥有大量未满足需求及长期增长潜力的主要治疗领域推进候选产品的差异化创新管 线。 ...

12月19日，联化科技（002250）披露投资者关系活动记录，公司于当日以特定对象调研形式接待了国海 证券、野村资管、易方达、湘财基金、国诚投资等5家机构的调研。公司高级副总裁、董秘陈飞彪及证 券事务代表戴依依参与接待，就公司植保业务布局、医药CDMO发展、研发创新方向及资本运作计划等 核心问题与机构进行了深入交流。 投资者关系活动基本信息投资者关系活动类别：特定对象调研时间：2025年12月19日地点：上海办会议 室参与单位名称：国海证券、野村资管、易方达、湘财基金、国诚投资上市公司接待人员：高级副总 裁、董秘 陈飞彪；证券事务代表 戴依依 调研核心内容解读植保业务：加码海外基地布局 构建差异化供应链 针对机构关注的植保业务规划，公司表示，植保行业集中度较高，公司已与多家国际农化/植保企业建 立长期战略合作伙伴关系，业务覆盖产品生命周期全阶段。为满足客户供应链布局需求，公司正将马来 西亚打造为"差异化的供应链布局"第二海外基地，协同中国、英国及马来西亚三地生产基地，利用中国 完善的化工供应链配套、英国及马来西亚灵活的生产及登记政策，为客户提供全产业链一站式服务。未 来，植保业务CDMO领域有望持续稳步发展。 ...

Group 1 - The CXO industry is entering a new high prosperity cycle driven by three factors: overseas interest rate cuts, domestic recovery, and industrial upgrades [2] - The report highlights the significant opportunities for the Chinese CXO industry due to industrial upgrades, particularly in new molecules like peptides, ADCs, and oligonucleotides [2] - External demand CXO companies are expected to recover by the second half of 2024, with a potential increase in orders and revenue in the first three quarters of 2025 [2] Group 2 - The chemical industry is facing potential supply tightness, particularly in the phosphate chemical sector, driven by strong demand for lithium iron phosphate and rising electricity costs [3] - The barriers to phosphate mining and processing are increasing, which may lead to lower-than-expected supply growth, keeping prices at high levels [3] - The market has shown a collective rebound, with significant trading volume, indicating a potential stabilization and recovery in market sentiment [3]

Investment Rating - The report maintains an "Overweight" rating for the CXO industry, indicating a positive outlook for investment opportunities in this sector [7]. Core Insights - The CXO industry is entering a new high prosperity cycle driven by external factors such as overseas interest rate cuts, domestic recovery, and industrial upgrades. The worst period for the industry is considered to be over, with a significant improvement in sentiment and operational conditions [1][2][17]. - The report emphasizes the competitive advantages of Chinese CXO companies, including efficiency, cost, quality, and rapid expansion capabilities, which are expected to maintain their global standing in the short to medium term [1][3][22]. - The emergence of new molecular drugs, such as peptides and oligonucleotides, is driving growth in the CRDMO sector, with Chinese suppliers positioned to lead globally due to their production capabilities and cost advantages [3][22][28]. Summary by Sections New Cycle - The CXO industry has transitioned from a prolonged adjustment period (2H21-1H24) to a new upward cycle, supported by recovering overseas financing and a favorable domestic IPO environment. The demand for CXO services is expected to increase significantly starting in 2026 [2][17]. New Molecules - New molecular CRDMO services are characterized by higher demand and technical barriers. Chinese companies are leading in areas like TIDES and ADC, achieving higher growth rates and maintaining robust profit margins [3][22][28]. New Landscape - The domestic CXO market is undergoing a restructuring, with market share increasingly concentrated among leading firms. The report highlights that smaller companies may struggle to survive due to heightened quality and sustainability demands from pharmaceutical clients [4][22][28]. Key Recommendations - The report recommends investing in leading companies with strong positions in the new molecular space, such as WuXi AppTec, WuXi Biologics, and others, which are expected to benefit from the ongoing industry upgrades and demand recovery [1][9][22].

Core Viewpoint - The biopharmaceutical sector is expected to experience significant performance divergence among its sub-sectors before the third quarter of 2025, with industry revenue and profit growth rates initially declining before rebounding, as the pressures from high baselines, centralized procurement, and anti-corruption measures have been largely absorbed [1] Group 1: Innovative Drugs - The commercial insurance innovation drug catalog is set to debut in 2025, which is anticipated to drive incremental payments for innovative drug products [2] - The domestic new drug development is accelerating, with lower costs and favorable macro policies, leading to a global leadership position in innovative drug development, contributing approximately one-third of the global innovative R&D pipeline by 2025 [2] - The overseas rights BD transactions are driving the revaluation of innovative drug assets, with a continuous increase in the proportion of Chinese innovative drug license-outs [2] Group 2: CXO and Life Sciences - The CXO market is witnessing improved supply-demand dynamics, with CDMO companies entering a high prosperity cycle due to strong demand for new molecules like ADCs and peptides [2] - The life sciences upstream sector is experiencing a comprehensive recovery in downstream demand, with listed companies actively pursuing mergers and acquisitions to expand [3] Group 3: AI in Healthcare - The "Artificial Intelligence+" policy is leading to widespread applications of AI in healthcare, with significant developments driven by companies like Deepseek [3] Group 4: High-end Medical Equipment - The high-end medical equipment sector is poised for growth due to domestic procurement recovery, import substitution, and accelerated international expansion [3] Group 5: Orthopedic Joint Consumables - The negative impact of centralized procurement is clearing, and the aging population is driving market expansion, with potential growth in surgical robotics [3] Group 6: Traditional Chinese Medicine - There are signs of operational improvement in traditional Chinese medicine, with factors like flu season and basic drug catalog adjustments potentially catalyzing a new market cycle [4]

Core Viewpoint - The article systematically reviews the global development history of peptide research, particularly focusing on skin-active peptides, their discovery, mechanisms, clinical applications, and future research directions, highlighting significant milestones and breakthroughs in the field [3][7][43]. Development History of Peptides - The concept of "peptide" was first proposed by Hermann Emil Fischer in 1902, laying the foundation for peptide chemistry and subsequent research in skin-active peptides [9][10]. - In 1922, insulin became the first peptide drug extracted from animal pancreas, demonstrating the biological activity and therapeutic potential of peptides [11]. - The 1950s saw significant breakthroughs in peptide synthesis techniques, including the total synthesis of oxytocin and vasopressin, which opened new avenues for peptide production [12][13]. Key Discoveries and Applications - The discovery of GHK-Cu (blue copper peptide) in 1973 marked a turning point in skin-active peptide research, proving the biological basis for small peptides in skin regulation and repair [17]. - The introduction of palmitoyl tripeptide-1 and palmitoyl hexapeptide-12 in 1992 represented a shift towards biomimetic signaling functions in cosmetic applications [29][31]. - The 2000s saw the emergence of neuropeptide inhibitors like acetyl hexapeptide-3, which mimic the effects of botulinum toxin without the need for injections, becoming popular in anti-aging products [33]. Current Research Trends - AI-assisted peptide design and transdermal delivery technology are at the forefront of current research, significantly shortening development cycles and improving delivery efficiency [37][38]. - The use of enzymatic hydrolysis and recombinant DNA technology has become prevalent in producing bioactive peptides, enhancing the feasibility of large-scale production [28][39]. Future Directions - Future research is expected to focus on overcoming challenges related to synthesis complexity, stability, and regulatory compliance, with an emphasis on personalized skincare solutions based on individual skin characteristics [45][47]. - The rise of Chinese research teams, exemplified by Han Shu's development of ring hexapeptide-9, signifies a growing presence in the global peptide market, showcasing innovation in cosmetic ingredients [39][41][42].

Core Viewpoint - The pharmaceutical sector has shown a volatile upward trend since early 2025, with a brief correction highlighting its cost-effectiveness, despite current valuations being at historical medians since 2010, indicating room for market capitalization growth [1] Group 1: Innovative Drug Industry Chain - Emphasis on innovation and the importance of high-quality domestic clinical data to catalyze opportunities for profit recovery in the industry [2] - Domestic assets are gaining global recognition, with strong demand for new product iterations and favorable conditions for domestic new drugs to enter international markets [2] - The dual-antibody market (PD-(L)1/VEGF) is experiencing increasing market heat and transaction value, with potential for synergistic effects alongside ADC mechanisms [2] Group 2: New Therapeutic Approaches - High demand for new therapies such as peptides, ADCs, small nucleic acids, and CGT is expected to maintain rapid growth, with a recovery in outsourcing demand anticipated during the overseas interest rate decline [3] - The domestic market is poised for a recovery in demand and primary market conditions, with a potential for rapid profit recovery as supply-side capacity reduction slows [3] Group 3: Non-Pharmaceutical Sector - Medical devices are showing signs of a turning point, with growth stabilizing for certain companies and a recovery in bidding processes expected to impact 2026 performance positively [4] - The traditional Chinese medicine sector is likely to see continued adjustments in essential drug catalogs, with opportunities arising from price declines in raw materials [4] - Retail pharmacies are undergoing accelerated consolidation, with leading pharmacies optimizing store structures to alleviate profit pressures, leading to expected profit margin improvements in 2026 [4]

Investment Strategy Overview - The core investment strategy for the pharmaceutical sector in 2026 emphasizes innovation and the recovery of profitability within the industry, as the sector has shown signs of stabilization after a period of volatility [4][30]. Innovative Drug Industry Chain - The domestic innovative drug sector is gaining global recognition, with a significant increase in the attention from multinational corporations (MNCs) towards domestic assets. The demand for new products is strong, driven by the approaching patent cliffs for MNCs and favorable policies for domestic drugs entering international markets [5][44]. - The market for PD-(L)1/VEGF bispecific antibodies is experiencing heightened interest, with complementary mechanisms to antibody-drug conjugates (ADCs) expected to drive synergy and growth [5][51]. - The demand for new therapeutic modalities such as peptides, ADCs, small nucleic acids, and cell and gene therapies (CGT) is projected to maintain high growth rates, supported by a recovering outsourcing demand during the overseas interest rate decline [6][43]. Non-Pharmaceutical Sector - The medical device sector is showing signs of recovery, with some companies reporting improved performance in Q3 2025. The bidding for medical equipment is expected to continue recovering, leading to better performance in 2026 [6][7]. - The traditional Chinese medicine sector is anticipated to benefit from ongoing adjustments to the essential drug list, with opportunities for price increases and improved profit margins for leading companies [6][7]. Retail Pharmacy Sector - The retail pharmacy industry is undergoing accelerated consolidation, with leading pharmacies optimizing their store structures to alleviate profit pressures. This is expected to result in a noticeable improvement in profit margins in 2026 [7]. Market Performance and Valuation - The pharmaceutical sector has shown a rebound since early 2025, with a notable increase in the market index, outperforming the broader market indices. As of November 21, 2025, the CITIC Pharmaceutical Index had risen by 14.68% [15][30]. - The valuation of the pharmaceutical sector is at a historical median since 2010, with a price-to-earnings (PE) ratio of 48.38X, indicating a high premium compared to the broader market [17][30]. - The scale of pharmaceutical funds reached a record high of 226 billion yuan by Q3 2025, although the market capitalization of pharmaceutical stocks remains below historical peaks, suggesting potential for growth [20][24]. Financial Performance - The pharmaceutical sector's revenue for the first three quarters of 2025 was 185.46 billion yuan, reflecting a year-on-year decline of 1.34%. However, Q3 2025 showed a revenue increase of 1.18% compared to the previous quarter, indicating signs of recovery [30][31]. - The net profit attributable to shareholders for the pharmaceutical sector in the first three quarters of 2025 was 14.06 billion yuan, down 1.69% year-on-year, but with a positive growth of 3.61% in Q3 2025 compared to the previous quarter [30][31].